HR+/HER2- breast cancer

Latest news

Tag

Izalontamab Brengitecan in Heavily Pretreated HR+/HER2- Breast Cancer: Insights from the PANKU-Breast01 Phase 3 Trial in China

This review details the phase 3 PANKU-Breast01 trial evaluating izalontamab brengitecan versus chemotherapy in pretreated HR+/HER2- breast cancer, highlighting significant PFS improvement and safety considerations in a Chinese cohort.

Nov 5, 2026

news

Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results

The final TROPION-Breast01 analysis confirms datopotamab deruxtecan’s superior progression-free survival over chemotherapy in HR+/HER2- breast cancer. While overall survival did not reach significance, likely due to subsequent ADC cro

Jan 9, 2026

news

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

In a multicentre phase 2 single-arm trial, oral chidamide added to standard epirubicin–cyclophosphamide followed by docetaxel produced an RCB 0–I rate of 35.2% in stage II–III HR+/HER2– breast cancer, with high rates of grade 3–4 neutropeni

Nov 24, 2025